Related Experiment Videos
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients
R M Lowenthal1, C N Chesterman, J D Griffiths
1Department of Medicine, University of Tasmania Clinical School, Australia.
Abstract:
Oral idarubicin was given as single-agent treatment of acute nonlymphocytic leukemia in 18 poor-risk patients. They comprised nine previously untreated elderly patients, age range 69-86, and nine relapsed pretreated patients, age range 41-76. Overall, two patients achieved complete remission (including one with preceding refractory anemia with excess of blasts) and seven achieved partial responses. Dose-limiting toxic effects were diarrhea and sepsis. In this limited study, oral idarubicin at a dose of 20-25 mg/m2/day X 3 was a well-tolerated drug with potent antileukemic effects. The oral formulation deserves more widespread evaluation.